Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/lipid-nanoparticles.md — the filesystem corpus, unchanged. Not an edit.
12.4 kB
Revision 1
Revision 3
lines 8–16 → 8–167 unchanged lines not shown
categories: ["genetics", "nanomedicine"]categories: ["genetics", "nanomedicine"]tags: ["delivery", "mrna", "gene therapy", "crispr", "nanomedicine", "vaccines"]tags: ["delivery", "mrna", "gene therapy", "crispr", "nanomedicine", "vaccines"]summary: "Four-component lipid vesicles that carry mRNA and other nucleic acids into cells, the delivery system behind mRNA vaccines and the first systemic in vivo CRISPR therapies."summary: "Four-component lipid vesicles that carry mRNA and other nucleic acids into cells, the delivery system behind mRNA vaccines and the first systemic in vivo CRISPR therapies."updated: "2026-07-27"updated: "2026-11-01"humanEvidence: "Billions of mRNA vaccine doses and an approved siRNA drug establish that the carrier works and is tolerated in people, and a phase 1 trial showed a single infusion of an LNP-delivered CRISPR editor cut circulating transthyretin."humanEvidence: "Billions of mRNA vaccine doses and an approved siRNA drug establish that the carrier works and is tolerated in people, and a phase 1 trial showed a single infusion of an LNP-delivered CRISPR editor cut circulating transthyretin."access: "Approved LNP products are in clinical use — mRNA vaccines at population scale, patisiran as an infused drug for a rare disease — while the genome-editing therapies using the same carrier are trial-only."access: "Approved LNP products are in clinical use (mRNA vaccines at population scale, patisiran as an infused drug for a rare disease), while the genome-editing therapies using the same carrier are trial-only."reversibility: "context"reversibility: "context"issues: ["The PCSK9 base-editing results are stated without a citation."]issues: ["The PCSK9 base-editing results are stated without a citation."]------lines 20–26 → 20–263 unchanged lines not shown
"caption": "Nucleic acid delivery system", "caption": "Nucleic acid delivery system", "rows": [ "rows": [ { "label": "Type", "value": "Non-viral nanocarrier" }, { "label": "Type", "value": "Non-viral nanocarrier" }, { "label": "Diameter", "value": "Roughly 60–100 nm" }, { "label": "Diameter", "value": "Roughly 60-100 nm" }, { "label": "Components", "value": "Ionizable lipid, phospholipid, cholesterol, PEG-lipid" }, { "label": "Components", "value": "Ionizable lipid, phospholipid, cholesterol, PEG-lipid" }, { "label": "Default destination", "value": "Hepatocytes" }, { "label": "Default destination", "value": "Hepatocytes" }, { "label": "First approved product", "value": "Onpattro, 2018" }, { "label": "First approved product", "value": "Onpattro, 2018" },lines 31–37 → 31–374 unchanged lines not shown
}}`````` **Lipid nanoparticles** are small synthetic vesicles, typically 60 to 100 nanometres across, that package fragile nucleic acids and ferry them across a cell membrane. They are the reason mRNA vaccines work, the reason the first systemically delivered CRISPR therapy reached patients, and — because they deposit their cargo overwhelmingly in the liver — the reason most in vivo genome-editing programmes as of 2026 target a hepatic gene. Unlike [[aav-vectors]], they carry no viral protein, provoke no lasting anti-vector immunity, and can be given more than once.**Lipid nanoparticles** are small synthetic vesicles, typically 60 to 100 nanometres across, that package fragile nucleic acids and ferry them across a cell membrane. They are the reason mRNA vaccines work and the reason the first systemically delivered CRISPR therapy reached patients. Because they deposit their cargo overwhelmingly in the liver, they are also the reason most in vivo genome-editing programmes as of 2026 target a hepatic gene. Unlike [[aav-vectors]], they carry no viral protein, provoke no lasting anti-vector immunity, and can be given more than once. ```keyfacts```keyfacts[[lines 47–59 → 47–599 unchanged lines not shown
The other three components are structural. A helper phospholipid, usually DSPC, and cholesterol set the particle's phase behaviour and rigidity; a polyethylene-glycol-conjugated lipid coats the surface, controls particle size during mixing, and slows opsonisation. The particles are made by rapid microfluidic mixing of a lipid-in-ethanol stream with an acidic aqueous stream containing the RNA, which drives self-assembly in milliseconds.The other three components are structural. A helper phospholipid, usually DSPC, and cholesterol set the particle's phase behaviour and rigidity; a polyethylene-glycol-conjugated lipid coats the surface, controls particle size during mixing, and slows opsonisation. The particles are made by rapid microfluidic mixing of a lipid-in-ethanol stream with an acidic aqueous stream containing the RNA, which drives self-assembly in milliseconds. Endosomal escape remains startlingly inefficient. Only a small percentage of internalised cargo reaches the cytosol; the rest is destroyed or recycled out. Most of the potency gains over fifteen years have come from screening thousands of ionizable-lipid structures rather than from any single conceptual advance, and the field still lacks a predictive theory of what makes one escape better than another. Self-assembling lipid vesicles are, in this sense, a cruder object than the addressable structures of [[dna-nanotechnology]] — and vastly more successful in the clinic.Endosomal escape remains inefficient. Only a small percentage of internalised cargo reaches the cytosol; the rest is destroyed or recycled out. Most of the potency gains over fifteen years have come from screening thousands of ionizable-lipid structures rather than from any single conceptual advance, and the field still lacks a predictive theory of what makes one escape better than another. Self-assembling lipid vesicles are, in this sense, a cruder object than the addressable structures of [[dna-nanotechnology]], and vastly more successful in the clinic. ## Development history## Development history Liposomal drug delivery dates to the 1960s, but the specific lineage behind modern particles runs through Pieter Cullis's laboratory in Vancouver and the companies that spun out of it. The key move, made in the late 2000s, was replacing permanently charged cationic lipids with ionizable ones whose pKa could be tuned; systematic structure-activity work identified formulations that delivered siRNA to hepatocytes at doses two orders of magnitude lower than earlier designs.[^semple2010]Liposomal drug delivery dates to the 1960s, but the specific lineage behind modern particles runs through Pieter Cullis's laboratory in Vancouver and the companies that spun out of it. The key move, made in the late 2000s, was replacing permanently charged cationic lipids with ionizable ones whose pKa could be tuned; systematic structure-activity work identified formulations that delivered siRNA to hepatocytes at doses two orders of magnitude lower than earlier designs.[^semple2010] That work produced patisiran, approved in 2018 as the first siRNA therapeutic and the first licensed nucleic-acid LNP drug. It also produced the delivery platform that the COVID-19 mRNA vaccines used two years later, at a scale — billions of doses — that settled questions about manufacturability and short-term safety no clinical trial programme could have settled alone.That work produced patisiran, approved in 2018 as the first siRNA therapeutic and the first licensed nucleic-acid LNP drug. It also produced the delivery platform that the COVID-19 mRNA vaccines used two years later, at a scale of billions of doses, which settled questions about manufacturability and short-term safety that no clinical trial programme could have settled alone. > [!key] What the vaccines proved> [!key] What the vaccines proved> Before 2020 the honest description of LNPs was a promising delivery technology with one approved product. Mass vaccination demonstrated tolerable reactogenicity across all ages, workable cold-chain logistics, and industrial-scale production. That evidence base is what made regulators willing to consider systemic in vivo genome editing a few years later.> Before 2020 the honest description of LNPs was a promising delivery technology with one approved product. Mass vaccination demonstrated tolerable reactogenicity across all ages, workable cold-chain logistics, and industrial-scale production. That evidence base is what made regulators willing to consider systemic in vivo genome editing a few years later.lines 62–68 → 62–682 unchanged lines not shown
Injected intravenously, a conventional LNP adsorbs apolipoprotein E from plasma. ApoE is a ligand for the low-density lipoprotein receptor, which hepatocytes display abundantly, and the particle is taken up as though it were a lipoprotein.[^akinc2010] The liver's fenestrated endothelium does the rest. This is convenient if the target gene is expressed in the liver and a hard obstacle otherwise.Injected intravenously, a conventional LNP adsorbs apolipoprotein E from plasma. ApoE is a ligand for the low-density lipoprotein receptor, which hepatocytes display abundantly, and the particle is taken up as though it were a lipoprotein.[^akinc2010] The liver's fenestrated endothelium does the rest. This is convenient if the target gene is expressed in the liver and a hard obstacle otherwise. Two approaches redirect the particles elsewhere. The first alters the formulation itself: adding a fifth charged lipid shifts the protein corona that forms in blood and, with it, the destination organ, sending particles preferentially to lung or spleen.[^cheng2020] The second attaches a targeting ligand — an antibody or peptide against a surface marker — to the PEG-lipid. Antibody-targeted particles have been used in animals to make chimeric antigen receptor T cells inside the body rather than in a manufacturing facility,[^rurik2022] and to reach haematopoietic stem cells in the marrow, which if it translated would remove the chemotherapy conditioning that limits [[casgevy]] and similar products.Two approaches redirect the particles elsewhere. The first alters the formulation itself: adding a fifth charged lipid shifts the protein corona that forms in blood and, with it, the destination organ, sending particles preferentially to lung or spleen.[^cheng2020] The second attaches a targeting ligand, an antibody or peptide against a surface marker, to the PEG-lipid. Antibody-targeted particles have been used in animals to make chimeric antigen receptor T cells inside the body rather than in a manufacturing facility,[^rurik2022] and to reach haematopoietic stem cells in the marrow, which if it translated would remove the chemotherapy conditioning that limits [[casgevy]] and similar products. Neither approach has yet produced an approved extrahepatic product. Local administration sidesteps the problem where anatomy allows: inhaled particles for airway disease, intramuscular injection for vaccines, intratumoural injection in oncology.Neither approach has yet produced an approved extrahepatic product. Local administration sidesteps the problem where anatomy allows: inhaled particles for airway disease, intramuscular injection for vaccines, intratumoural injection in oncology. lines 72–78 → 72–783 unchanged lines not shown
The proof came with NTLA-2001, which delivers Cas9 mRNA and a guide targeting the transthyretin gene in hepatocytes. Interim results published in 2021 showed dose-dependent, durable falls in circulating transthyretin after a single infusion, with a mean reduction of roughly 87 percent at the higher dose tested.[^gillmore2021] It was the first demonstration that [[crispr-cas9]] could be administered systemically to a human being and knock out a gene in a solid organ. A companion programme knocking out prekallikrein for hereditary angioedema followed, and cardiovascular programmes using [[base-editing]] to disable PCSK9 have reported sustained reductions in LDL cholesterol after a single dose.The proof came with NTLA-2001, which delivers Cas9 mRNA and a guide targeting the transthyretin gene in hepatocytes. Interim results published in 2021 showed dose-dependent, durable falls in circulating transthyretin after a single infusion, with a mean reduction of roughly 87 percent at the higher dose tested.[^gillmore2021] It was the first demonstration that [[crispr-cas9]] could be administered systemically to a human being and knock out a gene in a solid organ. A companion programme knocking out prekallikrein for hereditary angioedema followed, and cardiovascular programmes using [[base-editing]] to disable PCSK9 have reported sustained reductions in LDL cholesterol after a single dose. The most striking application to date treated one patient. In 2025 a team at the University of Pennsylvania and the Children's Hospital of Philadelphia designed, manufactured, and administered a base-editing therapy for an infant with a severe urea-cycle disorder, moving from the identification of his specific mutation to first dose in about six months.[^musunuru2025] The therapy exists for a single person and cannot be commercialised in any conventional sense, which makes it an unsolved problem for regulators and payers as much as a technical achievement. It is also the clearest illustration of a general point: platform delivery plus programmable editing means the bottleneck for ultra-rare disease is no longer biology, and the arguments in [[access-and-inequality]] apply with unusual force.The most striking application to date treated one patient. In 2025 a team at the University of Pennsylvania and the Children's Hospital of Philadelphia designed, manufactured, and administered a base-editing therapy for an infant with a severe urea-cycle disorder, moving from the identification of his specific mutation to first dose in about six months.[^musunuru2025] The therapy exists for a single person and cannot be commercialised in any conventional sense, which makes it an unsolved problem for regulators and payers as much as a technical achievement. It is also the clearest illustration that platform delivery plus programmable editing means the bottleneck for ultra-rare disease is no longer biology, and the arguments in [[access-and-inequality]] apply with unusual force. ## Limitations and risks## Limitations and risks lines 84–90 → 84–905 unchanged lines not shown
## Outlook## Outlook The near-term trajectory is more editing programmes in the liver, where the technology already works, and a slow attack on everything else. If antibody-targeted particles reach blood stem cells in humans at useful efficiency, the consequences would be larger than any single therapy: inherited blood disease could be treated by injection rather than transplantation. Extending the same logic to muscle, brain, or the immune system would broaden genetic medicine well beyond the few hundred conditions currently in reach, and would be relevant to speculative programmes such as [[gene-therapy-for-aging]] that require repeated dosing across many tissues. Whether that happens depends on a problem the field has not solved in twenty years of effort — getting a nanoparticle to a chosen cell type without the liver taking it first, the same obstacle that has defeated most claims made for [[targeted-drug-delivery]] and for [[medical-nanorobots]].The near-term trajectory is more editing programmes in the liver, where the technology already works, and a slow attack on everything else. If antibody-targeted particles reach blood stem cells in humans at useful efficiency, the consequences would be larger than any single therapy: inherited blood disease could be treated by injection rather than transplantation. Extending the same logic to muscle, brain, or the immune system would broaden genetic medicine well beyond the few hundred conditions currently in reach, and would be relevant to speculative programmes such as [[gene-therapy-for-aging]] that require repeated dosing across many tissues. Whether that happens depends on a problem the field has not solved in twenty years of effort: getting a nanoparticle to a chosen cell type without the liver taking it first. That is the same obstacle that has defeated most claims made for [[targeted-drug-delivery]] and for [[medical-nanorobots]]. ## See also## See also lines 96–101 → 96–1025 unchanged lines not shown
- [[targeted-drug-delivery]]- [[targeted-drug-delivery]]- [[dna-nanotechnology]]- [[dna-nanotechnology]]- [[germline-editing]]- [[germline-editing]]- [[in-vivo-car-t]] ## References## References removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
99 lines are the same in both revisions, and 45 of them are not shown. Neither revision here is necessarily the current article — read Lipid nanoparticles for the text this wiki stands behind today.